Gibson, Dunn & Crutcher LLP fields a broad life sciences practice advising biotech, pharma, medical device, and diagnostics companies on transactional and IP matters. The firm handles mergers and acquisitions, capital markets transactions, debt financings, and private equity investments, alongside a strong focus on patent litigation. Ryan Murr, co-chair of the life sciences practice, advises public and private life sciences companies and investors on securities offerings and business combination transactions, working from San Francisco. Jane Love, also co-chair and based in New York, represents pharma and biotech companies in high-value patent litigation, including global disputes.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Lawyer & team quality
Client satisfaction: Billing & efficiency
Client satisfaction: Sector knowledge
Client satisfaction: NPS ®
Key clients
- Sun Pharmaceutical Industries, Inc.
- Advanced Accelerator Applications USA, Inc. (ADACAP)
- Novartis
- UnitedHealth Group and its subsidiaries, OptumRx, Inc.
- Merck & Co., Inc.
- Amgen, Inc.
- AbbVie, Inc.
- 89bio, Ltd.
- Royalty Pharma
- Alcon, Inc.
- Arrowhead Pharmaceuticals, Inc.
- Jade Biosciences, Inc.
Work highlights
Advised 89bio, on its sale to Roche Holdings.
Enabled Sun Pharma’s product launch and clarified standards in disputes concerning innovative therapies.
Represents Advanced Accelerator Applications in patent matters involving Lutathera.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Ryan Murr; Jane M. Love
Other key lawyers
Branden Berns; Karen Spindler; Eric J. Stock